Inflammation following traumatic brain injury (TBI) may contribute to long-term morbidity. We aimed to characterize plasma interleukin-6 (IL6) trajectory after TBI and assess associations with imaging, biomarkers, and outcomes. Secondary analysis of three prospective multicenter observational cohorts: BIO-AX-TBI (Unite...
Leo Layzell, E. Kodosaki, Xiaoying Sun et al.· Neurotrauma Reports· 0 citations
Multiple plasma proteins are elevated in presymptomatic and symptomatic ADAD mutation carriers relative to non-carriers, and combining biomarkers may help in staging presymptomatic AD and optimise clinical trial inclusion.
C. Belder, A. Heslegrave, O. Swann et al.· Journal of Neurology Neurosu...· 1 citation
Dementia with Lewy Bodies (DLB) is the most common neurodegenerative dementia after Alzheimer’s disease (AD), but it remains challenging to diagnose due to overlapping symptoms and mixed pathologies. This pilot study tested whether DLB has different metabolic blood proteomic profiles compared to AD and controls. Serum...
Ariana Pritha, L. Chouliaras, P. Swann et al.· International Journal of Mol...· 0 citations
Together, these experiments show that GarsΔETAQ/+ mice display robust and selective peripheral nerve pathology that manifests in a general distal-to-proximal fashion, priming this CMT2D allele for testing treatments and evaluating mechanisms underlying peripheral nerve vulnerability.
R. Simkin, A. Paulo-Ramos, Qiuhan Lang et al.· bioRxiv· 0 citations
This study provides Class II evidence that plasma NfL/p-tau217 discriminates patients with CJD from those with AD and Diagnosing AD with a single abnormal p-tau plasma biomarker risks misdiagnosing prion diseases as AD.
Thomas Coysh, Rhiannon Laban, Elena Veleva et al.· Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
